1. Phylogeny  
Homeodomain‐interacting protein kinase 2 (HIPK2) is an evolutionarily conserved serine/threonine kinase that belongs to the HIPK family, which comprises four paralogues in mammals: HIPK1, HIPK2, HIPK3, and HIPK4. Among these, HIPK2 shares a high degree of similarity in the kinase domain with HIPK1 and HIPK3, whereas HIPK4 is more divergent. Orthologs of HIPK2 have been identified in a broad range of vertebrates, and the conservation of key regulatory mechanisms—such as the autophosphorylation events and binding interactions with cofactors like the prolyl isomerase Pin1—has been demonstrated in human cells and in model organisms such as zebrafish (bitomsky2013autophosphorylationandpin1 pages 1-2, conte2018updateonthe pages 2-3, isono2006overlappingrolesfor pages 1-2). Phylogenetically, HIPK2 is grouped within the CMGC kinase family, which includes kinases involved in cell cycle control and stress response; it is evolutionarily related to dual‐specificity tyrosine phosphorylation‐regulated kinases (DYRKs). The broad conservation of its catalytic features across species underscores the significance of HIPK2 in controlling fundamental cellular processes such as transcription regulation, apoptosis, and the response to DNA damage.

2. Reaction Catalyzed  
The catalytic function of HIPK2 is defined by its ability to transfer a phosphate group from ATP to specific serine or threonine residues on substrate proteins. In biochemical terms, this reaction is generally represented as:  
  ATP + protein–OH → ADP + protein–O‑phosphate + H⁺  
This central reaction underlies the kinase’s role in signal transduction. In addition to phosphorylating downstream targets, HIPK2 is also capable of autophosphorylation. For example, in response to genotoxic stress, HIPK2 autophosphorylates at specific residues (such as Thr880 and Ser882), a modification that enhances its catalytic activity and facilitates its role in initiating apoptotic signaling cascades (bitomsky2013autophosphorylationandpin1 pages 1-2, cozza2014synthesisandproperties pages 1-2). The reaction catalyzed by HIPK2 thus conforms to the typical mechanism observed in serine/threonine kinases, where the activated enzyme transfers a phosphate from ATP to its protein substrate to effect changes in activity, stability, localization, or interaction with other factors.

3. Cofactor Requirements  
The kinase activity of HIPK2, like that of other serine/threonine kinases, is dependent upon the presence of ATP as the phosphate donor. In addition, a divalent metal ion—most commonly magnesium (Mg²⁺)—serves as a critical cofactor. The Mg²⁺ ion coordinates with the phosphates of ATP, thereby stabilizing the nucleotide in a conformation that is conducive to the transfer of the gamma-phosphate group to the substrate hydroxyl group (cozza2014synthesisandproperties pages 1-2, laden2015effectoftyrosine pages 1-2). This requirement for Mg²⁺ is a hallmark of protein kinases and is essential for ensuring efficient phosphoryl transfer during the catalytic cycle.

4. Substrate Specificity  
HIPK2 phosphorylates serine/threonine residues on a variety of substrates that are central to the regulation of transcription, cell cycle progression, and apoptosis. One of the most critical substrates of HIPK2 is the tumor suppressor protein p53, which is phosphorylated by HIPK2 at serine 46; this modification is instrumental in shifting p53’s transcriptional program toward the induction of apoptosis (bitomsky2013autophosphorylationandpin1 pages 4-4, rinaldo2007hipk2amultitalented pages 5-6). In addition, HIPK2 targets numerous transcription factors and coregulators, including SMAD1, POU4F1/Brn3a, and others such as CTBP1, CBX4, RUNX1, EP300, CTNNB1, HMGA1, ZBTB4, and DAZAP2. Despite the extensive list of substrates, the precise consensus sequence or substrate motif for HIPK2 is not explicitly defined in the literature provided; however, the enzyme clearly exhibits a substrate preference for serine/threonine residues located in regions that regulate transcriptional activity and apoptosis (bitomsky2013autophosphorylationandpin1 pages 4-4, rinaldo2007hipk2amultitalented pages 5-6). This broad substrate specificity enables HIPK2 to function as a key modulator of cell fate through post-translational modification of proteins involved in both pro-apoptotic and anti-proliferative signaling networks.

5. Structure  
HIPK2 is composed of several distinct structural domains that contribute both to its catalytic function and to its role in signal transduction. At the N-terminus, HIPK2 contains a conserved kinase domain that is responsible for its catalytic activity. This domain features essential catalytic motifs, including a critical lysine residue (for example, K221) that is indispensable for ATP binding and phosphoryl transfer. The activation loop within this kinase domain is a key regulatory region where autophosphorylation occurs; specific residues within the activation loop (such as Thr880 and Ser882) are phosphorylated in response to DNA damage, thereby enhancing HIPK2’s activity (bitomsky2013autophosphorylationandpin1 pages 1-2, scaglione2018effectsofy361‐auto‐phosphorylation pages 1-2).  

Immediately following the kinase domain, HIPK2 harbors a homeodomain-interacting domain. This region is essential for mediating physical interactions with homeodomain transcription factors, which underpins HIPK2’s role as a transcriptional corepressor. In addition, HIPK2 contains regulatory regions such as a PEST sequence that may signal the protein for degradation via the proteasome; this is complemented by a speckle-retention signal that is crucial for subnuclear localization, particularly to nuclear speckles and promyelocytic leukemia (PML) nuclear bodies (rinaldo2007hipk2amultitalented pages 7-8, pierantoni2001highmobilitygroup pages 4-5). A further regulatory element is the autoinhibitory domain; removal or cleavage of this domain results in a hyperactive kinase, thus demonstrating its role in tempering HIPK2’s catalytic output. Structural studies, including recent crystal structure analyses, have confirmed that the HIPK2 kinase domain adopts the canonical bilobal fold characteristic of serine/threonine kinases, with a smaller N-terminal lobe primarily composed of β-strands and a larger C-terminal lobe rich in α-helices. Key catalytic features—including the configuration of the activation loop, the positioning of the C-helix, and the alignment of the hydrophobic spines—are conserved in HIPK2, ensuring proper substrate engagement and efficient catalysis (cozza2014synthesisandproperties pages 8-8, murphy2019thelongawaitedstructure pages 1-2).

6. Regulation  
HIPK2 is subject to a complex array of regulatory mechanisms that modulate its enzymatic activity, stability, subcellular localization, and interactions with substrates. One of the primary modes of regulation is post-translational modification. Under conditions of DNA damage, HIPK2 undergoes oligomerization and site-specific autophosphorylation; for instance, autophosphorylation at residues such as Thr880 and Ser882 significantly enhances its kinase activity, thereby promoting apoptotic signaling (bitomsky2013autophosphorylationandpin1 pages 1-2, scaglione2018effectsofy361‐auto‐phosphorylation pages 1-2).  

In parallel, HIPK2 activity is tightly controlled by ubiquitination. In the absence of stress, several E3 ubiquitin ligases—including Siah-1, MDM2, and WSB-1—target HIPK2 for polyubiquitination and subsequent proteasomal degradation, thus maintaining low baseline levels of the kinase within the cell (d’orazi2012updatesonhipk2 pages 1-2, sombroek2009howcellsswitch pages 3-4). Upon exposure to genotoxic agents, DNA damage checkpoint kinases such as ATM and ATR are activated; these kinases modify components of the ubiquitin machinery, effectively reducing HIPK2 degradation and leading to its stabilization. This stabilization allows HIPK2 to accumulate and to phosphorylate key substrates such as p53, thereby triggering apoptotic pathways.  

Another critical layer of regulation involves SUMOylation. HIPK2 is covalently modified by the small ubiquitin-like modifier (SUMO), particularly at lysine 25, and contains SUMO-interacting motifs (SIMs) that facilitate its targeting to PML nuclear bodies. This localization is pivotal for the efficient phosphorylation of p53 at Ser46, as the PML nuclear bodies serve as hubs for the assembly of transcriptional and apoptotic regulators (rinaldo2007hipk2amultitalented pages 5-6, sung2011roleofthe pages 10-11). Additionally, the prolyl isomerase Pin1 interacts with the autophosphorylated form of HIPK2; this binding stabilizes the kinase and assists in maintaining its proper conformation for substrate recognition and catalytic activity (bitomsky2013autophosphorylationandpin1 pages 1-2).  

Collectively, these diverse regulatory inputs—autophosphorylation, ubiquitination, and SUMOylation—allow HIPK2 to function as a molecular switch that integrates stress signals and modulates downstream responses. The balance between its activation and degradation is crucial for ensuring an appropriate cellular response to DNA damage, thereby determining whether a cell undergoes repair, cell cycle arrest, or enters into programmed cell death (sombroek2009howcellsswitch pages 6-7, torrente2017crosstalkbetweennrf2 pages 6-7).

7. Function  
HIPK2 plays a central role in integrating various stress signals to regulate cell fate decisions, and its functional output is largely defined by its ability to modify key transcription factors and regulatory proteins through phosphorylation. One of the most studied functions of HIPK2 is its role in the DNA damage response. In response to severe genotoxic stress—such as that induced by ultraviolet (UV) irradiation, ionizing radiation (IR), or chemotherapeutic agents—HIPK2 is activated through autophosphorylation and stabilization mechanisms. Activated HIPK2 phosphorylates the tumor suppressor p53 at serine 46; this phosphorylation event is pivotal for shifting p53’s transcriptional activity toward the expression of pro-apoptotic genes, facilitating the induction of apoptosis in cells with irreparable DNA damage (bitomsky2013autophosphorylationandpin1 pages 4-4, d’orazi2012updatesonhipk2 pages 1-2).  

Beyond its interaction with p53, HIPK2 functions as a corepressor of several transcription factors. It interacts with and modulates the activity of homeodomain-containing proteins—including SMAD1, POU4F1/Brn3a, and potentially NK homeodomain transcription factors—thereby influencing the transcriptional programs that govern developmental processes and cellular differentiation. Moreover, HIPK2 phosphorylates a range of proteins involved in cell cycle regulation and apoptosis, such as CTBP1 and CTNNB1, leading to their proteasomal degradation. Through these actions, HIPK2 not only inhibits cell growth by downregulating pro-survival signals but also actively promotes apoptotic pathways via both p53-dependent and p53-independent mechanisms (rinaldo2007hipk2amultitalented pages 2-3, d’orazi2012updatesonhipk2 pages 4-5).  

HIPK2 also participates in hypoxic signaling. In conditions of low oxygen, it acts as a transcriptional co-suppressor of HIF1A, contributing to the regulation of gene expression changes that are critical for cellular adaptation to hypoxia. Additionally, in response to TGFβ signaling, HIPK2 cooperates with the regulator DAXX to activate the JNK pathway, linking it to complex networks that control cell survival and apoptosis (d’orazi2012updatesonhipk2 pages 1-2, torrente2017crosstalkbetweennrf2 pages 6-7).  

Furthermore, HIPK2 influences the transcriptional activation of TP73, an important p53 family member, thereby expanding its role in the regulation of cell death beyond just p53. Its activity in various signaling cascades positions HIPK2 as a critical tumor suppressor. The precise modulation of its enzymatic function is essential for eliciting appropriate responses to cellular stress, and dysregulation of HIPK2 activity has been associated with tumorigenesis and chemoresistance (hofmann2013hipk2atumour pages 2-3, rinaldo2007hipk2amultitalented pages 2-3). Overall, HIPK2 is a multifunctional kinase that, through the phosphorylation of key substrates, orchestrates a network of transcriptional and apoptotic processes that maintain cellular homeostasis in response to environmental and genotoxic stresses.

8. Other Comments  
Several experimental inhibitors that target HIPK2 have been developed, offering valuable tools for dissecting its function and potential therapeutic modulation. For instance, TBID—a selective ATP-competitive inhibitor—has been shown to inhibit HIPK2 activity effectively in vitro (cozza2014synthesisandproperties pages 1-2, cozza2014synthesisandproperties pages 8-8). In addition, abemaciclib, an FDA-approved inhibitor originally designed for cyclin-dependent kinases, has demonstrated potent inhibitory effects against HIPK family kinases, including HIPK2 (kaltheuner2021abemaciclibisa pages 1-2). The pharmacological targeting of HIPK2 is particularly relevant in the context of cancer, as deregulated HIPK2 activity, whether due to enhanced degradation, mislocalization, or failure in activation, has been observed in malignancies such as thyroid carcinomas, breast cancer, and acute myeloid leukemia (d’orazi2012updatesonhipk2 pages 5-7, hofmann2013hipk2atumour pages 8-9). Although specific disease-associated mutations in HIPK2 are not extensively documented in the provided literature, the loss or misregulation of its function contributes to defective p53-mediated apoptosis and may promote tumor progression and resistance to chemotherapy. Additionally, the ability of HIPK2 to act as a corepressor in the Wnt/β-catenin signaling pathway by inducing the degradation of CTBP1 and CTNNB1 further underscores its tumor suppressor role. These observations have spurred interest in developing and refining small-molecule inhibitors that can modulate HIPK2 activity, with the ultimate goal of harnessing its regulatory potential in therapeutic settings. The broad involvement of HIPK2 in diverse signaling pathways—including those controlling hypoxic responses and transcriptional regulation—highlights its significance as a multifunctional regulator whose activity must be precisely balanced to maintain normal cellular function.

9. References  
1. bitomsky2013autophosphorylationandpin1 pages 1-2  
2. bitomsky2013autophosphorylationandpin1 pages 4-4  
3. conte2018updateonthe pages 2-3  
4. cozza2014synthesisandproperties pages 1-2  
5. cozza2014synthesisandproperties pages 8-8  
6. d’orazi2012updatesonhipk2 pages 1-2  
7. d’orazi2012updatesonhipk2 pages 4-5  
8. d’orazi2012updatesonhipk2 pages 5-7  
9. hofmann2013hipk2atumour pages 2-3  
10. hofmann2013hipk2atumour pages 6-7  
11. hofmann2013hipk2atumour pages 10-10  
12. laden2015effectoftyrosine pages 1-2  
13. laden2015effectoftyrosine pages 11-11  
14. rinaldo2007hipk2amultitalented pages 2-3  
15. rinaldo2007hipk2amultitalented pages 7-8  
16. scaglione2018effectsofy361‐auto‐phosphorylation pages 1-2  
17. scaglione2018effectsofy361‐auto‐phosphorylation pages 11-12  
18. sombroek2009howcellsswitch pages 3-4  
19. sombroek2009howcellsswitch pages 6-7  
20. sombroek2009howcellsswitch pages 7-7  
21. sung2011roleofthe pages 10-11  
22. torrente2017crosstalkbetweennrf2 pages 6-7  
23. calzado2009fromtopto pages 1-3  
24. isono2006overlappingrolesfor pages 1-2  
25. kaltheuner2021abemaciclibisa pages 1-2  
26. murphy2019thelongawaitedstructure pages 1-2  
27. pierantoni2001highmobilitygroup pages 4-5

References

1. (bitomsky2013autophosphorylationandpin1 pages 1-2): Nadja Bitomsky, Elisa Conrad, Christian Moritz, Tilman Polonio-Vallon, Dirk Sombroek, Kathrin Schultheiss, Carolina Glas, Vera Greiner, Christoph Herbel, Fiamma Mantovani, Giannino del Sal, Francesca Peri, and Thomas G. Hofmann. Autophosphorylation and pin1 binding coordinate dna damage-induced hipk2 activation and cell death. Proceedings of the National Academy of Sciences, 110:E4203-E4212, Oct 2013. URL: https://doi.org/10.1073/pnas.1310001110, doi:10.1073/pnas.1310001110. This article has 58 citations.

2. (conte2018updateonthe pages 2-3): Andrea Conte and Giovanna Maria Pierantoni. Update on the regulation of hipk1, hipk2 and hipk3 protein kinases by micrornas. MicroRNA, 7:178-186, Sep 2018. URL: https://doi.org/10.2174/2211536607666180525102330, doi:10.2174/2211536607666180525102330. This article has 37 citations and is from a peer-reviewed journal.

3. (cozza2014synthesisandproperties pages 1-2): G. Cozza, S. Zanin, Renate Determann, M. Ruzzene, C. Kunick, and L. Pinna. Synthesis and properties of a selective inhibitor of homeodomain–interacting protein kinase 2 (hipk2). PLoS ONE, Feb 2014. URL: https://doi.org/10.1371/journal.pone.0089176, doi:10.1371/journal.pone.0089176. This article has 31 citations and is from a peer-reviewed journal.

4. (cozza2014synthesisandproperties pages 8-8): G. Cozza, S. Zanin, Renate Determann, M. Ruzzene, C. Kunick, and L. Pinna. Synthesis and properties of a selective inhibitor of homeodomain–interacting protein kinase 2 (hipk2). PLoS ONE, Feb 2014. URL: https://doi.org/10.1371/journal.pone.0089176, doi:10.1371/journal.pone.0089176. This article has 31 citations and is from a peer-reviewed journal.

5. (d’orazi2012updatesonhipk2 pages 1-2): Gabriella D’Orazi, Cinzia Rinaldo, and Silvia Soddu. Updates on hipk2: a resourceful oncosuppressor for clearing cancer. Journal of Experimental &amp; Clinical Cancer Research, Aug 2012. URL: https://doi.org/10.1186/1756-9966-31-63, doi:10.1186/1756-9966-31-63. This article has 95 citations.

6. (d’orazi2012updatesonhipk2 pages 4-5): Gabriella D’Orazi, Cinzia Rinaldo, and Silvia Soddu. Updates on hipk2: a resourceful oncosuppressor for clearing cancer. Journal of Experimental &amp; Clinical Cancer Research, Aug 2012. URL: https://doi.org/10.1186/1756-9966-31-63, doi:10.1186/1756-9966-31-63. This article has 95 citations.

7. (hofmann2013hipk2atumour pages 2-3): Thomas G. Hofmann, Carolina Glas, and Nadja Bitomsky. Hipk2: a tumour suppressor that controls dna damage‐induced cell fate and cytokinesis. BioEssays, Jan 2013. URL: https://doi.org/10.1002/bies.201200060, doi:10.1002/bies.201200060. This article has 90 citations and is from a peer-reviewed journal.

8. (hofmann2013hipk2atumour pages 6-7): Thomas G. Hofmann, Carolina Glas, and Nadja Bitomsky. Hipk2: a tumour suppressor that controls dna damage‐induced cell fate and cytokinesis. BioEssays, Jan 2013. URL: https://doi.org/10.1002/bies.201200060, doi:10.1002/bies.201200060. This article has 90 citations and is from a peer-reviewed journal.

9. (laden2015effectoftyrosine pages 1-2): Jan van der Laden, Ulf Soppa, and Walter Becker. Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (hipk). Cell Communication and Signaling, Jan 2015. URL: https://doi.org/10.1186/s12964-014-0082-6, doi:10.1186/s12964-014-0082-6. This article has 43 citations and is from a peer-reviewed journal.

10. (rinaldo2007hipk2amultitalented pages 2-3): Cinzia Rinaldo, Andrea Prodosmo, Francesca Siepi, and Silvia Soddu. Hipk2: a multitalented partner for transcription factors in dna damage response and developmentthis paper is one of a selection of papers published in this special issue, entitled 28th international west coast chromatin and chromosome conference, and has undergone the journal's usual peer review process. Biochemistry and Cell Biology, 85:411-418, Aug 2007. URL: https://doi.org/10.1139/o07-071, doi:10.1139/o07-071. This article has 140 citations.

11. (rinaldo2007hipk2amultitalented pages 7-8): Cinzia Rinaldo, Andrea Prodosmo, Francesca Siepi, and Silvia Soddu. Hipk2: a multitalented partner for transcription factors in dna damage response and developmentthis paper is one of a selection of papers published in this special issue, entitled 28th international west coast chromatin and chromosome conference, and has undergone the journal's usual peer review process. Biochemistry and Cell Biology, 85:411-418, Aug 2007. URL: https://doi.org/10.1139/o07-071, doi:10.1139/o07-071. This article has 140 citations.

12. (scaglione2018effectsofy361‐auto‐phosphorylation pages 1-2): Antonella Scaglione, Laura Monteonofrio, Giacomo Parisi, Cristina Cecchetti, Francesca Siepi, Cinzia Rinaldo, Alessandra Giorgi, Daniela Verzili, Carlotta Zamparelli, Carmelinda Savino, Silvia Soddu, Beatrice Vallone, and Linda Celeste Montemiglio. Effects of y361‐auto‐phosphorylation on structural plasticity of the hipk2 kinase domain. Protein Science, Mar 2018. URL: https://doi.org/10.1002/pro.3367, doi:10.1002/pro.3367. This article has 6 citations and is from a peer-reviewed journal.

13. (sombroek2009howcellsswitch pages 6-7): D Sombroek and T G Hofmann. How cells switch hipk2 on and off. Cell Death &amp; Differentiation, 16:187-194, Oct 2009. URL: https://doi.org/10.1038/cdd.2008.154, doi:10.1038/cdd.2008.154. This article has 85 citations.

14. (sombroek2009howcellsswitch pages 7-7): D Sombroek and T G Hofmann. How cells switch hipk2 on and off. Cell Death &amp; Differentiation, 16:187-194, Oct 2009. URL: https://doi.org/10.1038/cdd.2008.154, doi:10.1038/cdd.2008.154. This article has 85 citations.

15. (bitomsky2013autophosphorylationandpin1 pages 4-4): Nadja Bitomsky, Elisa Conrad, Christian Moritz, Tilman Polonio-Vallon, Dirk Sombroek, Kathrin Schultheiss, Carolina Glas, Vera Greiner, Christoph Herbel, Fiamma Mantovani, Giannino del Sal, Francesca Peri, and Thomas G. Hofmann. Autophosphorylation and pin1 binding coordinate dna damage-induced hipk2 activation and cell death. Proceedings of the National Academy of Sciences, 110:E4203-E4212, Oct 2013. URL: https://doi.org/10.1073/pnas.1310001110, doi:10.1073/pnas.1310001110. This article has 58 citations.

16. (d’orazi2012updatesonhipk2 pages 5-7): Gabriella D’Orazi, Cinzia Rinaldo, and Silvia Soddu. Updates on hipk2: a resourceful oncosuppressor for clearing cancer. Journal of Experimental &amp; Clinical Cancer Research, Aug 2012. URL: https://doi.org/10.1186/1756-9966-31-63, doi:10.1186/1756-9966-31-63. This article has 95 citations.

17. (hofmann2013hipk2atumour pages 10-10): Thomas G. Hofmann, Carolina Glas, and Nadja Bitomsky. Hipk2: a tumour suppressor that controls dna damage‐induced cell fate and cytokinesis. BioEssays, Jan 2013. URL: https://doi.org/10.1002/bies.201200060, doi:10.1002/bies.201200060. This article has 90 citations and is from a peer-reviewed journal.

18. (hofmann2013hipk2atumour pages 8-9): Thomas G. Hofmann, Carolina Glas, and Nadja Bitomsky. Hipk2: a tumour suppressor that controls dna damage‐induced cell fate and cytokinesis. BioEssays, Jan 2013. URL: https://doi.org/10.1002/bies.201200060, doi:10.1002/bies.201200060. This article has 90 citations and is from a peer-reviewed journal.

19. (isono2006overlappingrolesfor pages 1-2): Kyoichi Isono, Kazumi Nemoto, Yuanyuan Li, Yuki Takada, Rie Suzuki, Motoya Katsuki, Akira Nakagawara, and Haruhiko Koseki. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Molecular and Cellular Biology, 26:2758-2771, Apr 2006. URL: https://doi.org/10.1128/mcb.26.7.2758-2771.2006, doi:10.1128/mcb.26.7.2758-2771.2006. This article has 138 citations and is from a domain leading peer-reviewed journal.

20. (kaltheuner2021abemaciclibisa pages 1-2): Ines H. Kaltheuner, Kanchan Anand, Jonas Moecking, Robert Düster, Jinhua Wang, Nathanael S. Gray, and Matthias Geyer. Abemaciclib is a potent inhibitor of dyrk1a and hip kinases involved in transcriptional regulation. Nature Communications, Nov 2021. URL: https://doi.org/10.1038/s41467-021-26935-z, doi:10.1038/s41467-021-26935-z. This article has 29 citations and is from a highest quality peer-reviewed journal.

21. (laden2015effectoftyrosine pages 11-11): Jan van der Laden, Ulf Soppa, and Walter Becker. Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (hipk). Cell Communication and Signaling, Jan 2015. URL: https://doi.org/10.1186/s12964-014-0082-6, doi:10.1186/s12964-014-0082-6. This article has 43 citations and is from a peer-reviewed journal.

22. (murphy2019thelongawaitedstructure pages 1-2): James M. Murphy. The long-awaited structure of hipk2. Journal of Biological Chemistry, 294:13560-13561, Sep 2019. URL: https://doi.org/10.1074/jbc.h119.010675, doi:10.1074/jbc.h119.010675. This article has 3 citations and is from a domain leading peer-reviewed journal.

23. (pierantoni2001highmobilitygroup pages 4-5): G. Pierantoni, M. Fedele, F. Pentimalli, G. Benvenuto, Raffaela Pero, G. Viglietto, M. Santoro, L. Chiariotti, and A. Fusco. High mobility group i (y) proteins bind hipk2, a serine-threonine kinase protein which inhibits cell growth. Oncogene, 20:6132-6141, Sep 2001. URL: https://doi.org/10.1038/sj.onc.1204635, doi:10.1038/sj.onc.1204635. This article has 111 citations and is from a domain leading peer-reviewed journal.

24. (rinaldo2007hipk2amultitalented pages 5-6): Cinzia Rinaldo, Andrea Prodosmo, Francesca Siepi, and Silvia Soddu. Hipk2: a multitalented partner for transcription factors in dna damage response and developmentthis paper is one of a selection of papers published in this special issue, entitled 28th international west coast chromatin and chromosome conference, and has undergone the journal's usual peer review process. Biochemistry and Cell Biology, 85:411-418, Aug 2007. URL: https://doi.org/10.1139/o07-071, doi:10.1139/o07-071. This article has 140 citations.

25. (scaglione2018effectsofy361‐auto‐phosphorylation pages 11-12): Antonella Scaglione, Laura Monteonofrio, Giacomo Parisi, Cristina Cecchetti, Francesca Siepi, Cinzia Rinaldo, Alessandra Giorgi, Daniela Verzili, Carlotta Zamparelli, Carmelinda Savino, Silvia Soddu, Beatrice Vallone, and Linda Celeste Montemiglio. Effects of y361‐auto‐phosphorylation on structural plasticity of the hipk2 kinase domain. Protein Science, Mar 2018. URL: https://doi.org/10.1002/pro.3367, doi:10.1002/pro.3367. This article has 6 citations and is from a peer-reviewed journal.

26. (sombroek2009howcellsswitch pages 3-4): D Sombroek and T G Hofmann. How cells switch hipk2 on and off. Cell Death &amp; Differentiation, 16:187-194, Oct 2009. URL: https://doi.org/10.1038/cdd.2008.154, doi:10.1038/cdd.2008.154. This article has 85 citations.

27. (sung2011roleofthe pages 10-11): Ki Sa Sung, Yun-Ah Lee, Eui Tae Kim, Seung-Rock Lee, Jin-Hyun Ahn, and C. Choi. Role of the sumo-interacting motif in hipk2 targeting to the pml nuclear bodies and regulation of p53. Experimental cell research, 317 7:1060-70, Apr 2011. URL: https://doi.org/10.1016/j.yexcr.2010.12.016, doi:10.1016/j.yexcr.2010.12.016. This article has 64 citations and is from a peer-reviewed journal.

28. (torrente2017crosstalkbetweennrf2 pages 6-7): L. Torrente, Carlos Sánchez, R. Moreno, S. Chowdhry, P. Cabello, K. Isono, H. Koseki, T. Honda, J. Hayes, A. Dinkova-Kostova, and L. D. L. Vega. Crosstalk between nrf2 and hipk2 shapes cytoprotective responses. Oncogene, 36:6204-6212, Jul 2017. URL: https://doi.org/10.1038/onc.2017.221, doi:10.1038/onc.2017.221. This article has 102 citations and is from a domain leading peer-reviewed journal.

29. (calzado2009fromtopto pages 1-3): Marco A. Calzado, Laureano De La Vega, Eduardo Munoz, and M. Lienhard Schmitz. From top to bottom: the two faces of hipk2 for regulation of the hypoxic response. Cell Cycle, 8:1659-1664, Jun 2009. URL: https://doi.org/10.4161/cc.8.11.8597, doi:10.4161/cc.8.11.8597. This article has 30 citations and is from a peer-reviewed journal.